[VIRTUAL] Targeting p53 in MDS (SOHO 2021) - May 20, 2021 - Abstract #EXABS-173-MDS; Pres time: Sep 8, 2021; 02:43 PM - 02:58 PM; Location: LEVEL 4, GRAND BALLROOM G-L; P1, P1b, P1b/2, P2, P3 | "Lastly, a 2nd generation oral agent (APR-548) will enter the clinic in 2021...These data support the planned Phase 3 open-label study of azacitidine + magrolimab versus azacitidine + venetoclax in unfit AML patients and versus induction chemotherapy in fit patients with a primary endpoint of OS in the non-intensive group (NCT04778397). Other novel HMA combinations have recently had high ORR/CR rates as frontline therapy, which include sabatolimab and pevonedistat, although unclear molecular subset data in TP53 mutant patients...Specifically, PDL1 has been shown to be upregulated on TP53 mutant hematopoietic stem cells and bone marrow blasts.17,18 Importantly, TP53 mutant AML patients have been strongly associated with an adverse immune microenvironment and potentially may be an optimal molecular subset for novel immunomodulatory agents.19 In this regard the bispecific agent flotetuzumab targeting CD123 has had activity in TP53 mutant...
IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • CD123 • TP53
|